BOOSTRIX is a vaccine indicated for active booster immunization against tetanus, diphtheria, and pertussis. BOOSTRIX is approved for use as a single dose in individuals aged 10 years and older.
Severe allergic reaction after a previous dose of any tetanus toxoid-, diphtheria toxoid-, or pertussis antigen-containing vaccine, or to any component of BOOSTRIX, or encephalopathy within 7 days of a previous pertussis antigen-containing vaccine is a contraindication.
Safety profile of BOOSTRIX in adolescents 10-18 years of age and adults 19-64 years of age
† Mid-upper region of the vaccinated arm.
‡ Gastrointestinal symptoms included nausea, vomiting, diarrhea, and/or abdominal pain.
§ Oral temperatures or axillary temperatures.
ii Oral temperatures.
Td = tetanus and diphtheria.
Tdap = tetanus, diphtheria, and acellular pertussis.
Safety profile of BOOSTRIX in adults 65 years of age and older
Solicited local reactions or general adverse events within 4 days of vaccination
* Gastrointestinal symptoms included nausea, vomiting, diarrhea, and/or abdominal pain.
† Oral temperatures.
- Prescribing Information for BOOSTRIX.
- Prescribing Information for Adacel.
- Pichichero ME, Blatter MM, Kennedy WA, Hedrick J, Descamps D, Friedland LR. Acellular pertussis vaccine booster combined with diphtheria and tetanus toxoids for adolescents. Pediatrics. 2006;117(4):1084-1093.
- Blatter M, Friedland LR, Weston WM, Li P, Howe B. Immunogenicity and safety of a tetanus toxoid, reduced diphtheria toxoid and three-component acellular pertussis vaccine in adults 19-64 years of age. Vaccine. 2009;27(5):765-772.
- American Medical Association. 2013 Current Procedural Terminology (CPT) Professional Edition. 4th rev ed. Chicago, IL: American Medical Association; 2012.